k. a. GM102) in different xenograft models, treatment with GM102 in a phase I clinical trial showed that 8/17 (47%) evaluable patients with ovarian cancer exhibited decreased tumor growth rates ranging from 45%–69% thereby indicating the potential for ovarian cancer immunotherapy with mAbs specific for AMHR2-ED [30] even if the humanized therapeutic mAb fails to induce apoptotic signaling [26, 27]. Here, AMHR2 is linked to neoplasm.